<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34303675</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1520-6017</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>110</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of pharmaceutical sciences</Title>
          <ISOAbbreviation>J Pharm Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effect of Dihydropyridine Enrichment in the Microstructure of the Palisade Layer on the Stability of Fat Nano-emulsions.</ArticleTitle>
        <Pagination>
          <StartPage>3648</StartPage>
          <EndPage>3658</EndPage>
          <MedlinePgn>3648-3658</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xphs.2021.07.013</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0022-3549(21)00369-5</ELocationID>
        <Abstract>
          <AbstractText>Relationship between the stability of fat nano-emulsions and the incorporated drug at the molecular level are rarely known. Herein, fat nano-emulsions containing dihydropyridine drugs were prepared and the microstructure of their palisade layers were investigated.The prepared 1.0 mg/mL nimodipine nano-emulsion was found to contain 65.50% drug in the palisade layer. The increasing drug concentration led to a decrease-increase-decrease trend in centrifugal stability constant, particle size and proton nuclear magnetic resonance (<sup>1</sup>H NMR) signal intensity of the lecithin trimethyl ammonium group in the nimodipine and felodipine nano-emulsions. The <sup>1</sup>H NMR spectra of test solutions including nano-emulsions suggest that increasing drugs penetrated into the palisade layer, resulting in the lecithin arrangement from loose to tight, and then from monolayer to bilayer. Nimodipine and felodipine nano-emulsions showed two valley values at concentrations of 0.15 and 0.75 mg/mL, and 0.30 and 0.90 mg/mL respectively, which indicated that the nano-emulsion has two more stable states corresponding to the tightly arranged mono- and bi-palisade layer. These two concentrations are positively correlated with lipophilicity of nimodipine and felodipine. Further, nimodipine liposomes were prepared to validate the effect of drugs on the arrangement of lecithin in the palisade layer. <sup>1</sup>H NMR characterizations of the liposomes showed a similar profile to that of nano-emulsions. These results demonstrated that the increasing drug concentration could cause a rearrangement of lecithin in the palisade layer, thus affecting emulsion stability.</AbstractText>
          <CopyrightInformation>Copyright © 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Haonan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Jiawei</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>The Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Cuicui</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>The Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>The Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Jiaqi</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>The Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Wenfang</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>The Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pang</LastName>
            <ForeName>Jiali</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>The Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>The Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China; Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, Department of Pharmaceutics, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China. Electronic address: yangwei029@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Fan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>The Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China; Guangdong Provincial Key Laboratory of Advanced Drug Delivery Systems, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China; Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, Department of Pharmaceutics, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China. Electronic address: gzyangfan@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Laiyou</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China; Department of Clinical Pharmacy, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080,Guangdong, China. Electronic address: laiyouwang@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Pharm Sci</MedlineTA>
        <NlmUniqueID>2985195R</NlmUniqueID>
        <ISSNLinking>0022-3549</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004095">Dihydropyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004655">Emulsions</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054709">Lecithins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D004095" MajorTopicYN="Y">Dihydropyridines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004655" MajorTopicYN="N">Emulsions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054709" MajorTopicYN="Y">Lecithins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Fat nano-emulsion</Keyword>
        <Keyword MajorTopicYN="Y">Felodipine</Keyword>
        <Keyword MajorTopicYN="Y">Nimodipine</Keyword>
        <Keyword MajorTopicYN="Y">Nuclear magnetic resonance</Keyword>
        <Keyword MajorTopicYN="Y">Palisade layer</Keyword>
        <Keyword MajorTopicYN="Y">Stability</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors report no conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>25</Day>
          <Hour>20</Hour>
          <Minute>28</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34303675</ArticleId>
        <ArticleId IdType="doi">10.1016/j.xphs.2021.07.013</ArticleId>
        <ArticleId IdType="pii">S0022-3549(21)00369-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
